Carlo Banez (talk | contribs) m moved Gadopentetate dimeglumine to Gadopentetic acid: moving to INN as per Wikipedia:WikiProject Pharmacology/Style guide#Drug pages to use INN |
Carlo Banez (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{drugbox |IUPAC_name=2-[bis[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium( +3) cation; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol |image= |CAS_number=86050-77-3 |ATC_prefix= |ATC_suffix= |ATC_supplemental= |PubChem=55466 |DrugBank=DB00789 |chemical_formula=C<sub>28</sub>H<sub>54</sub>GdN<sub>5</sub>O<sub>20</sub> |molecular_weight= |bioavailability= |protein_bound= |metabolism= |elimination_half-life=Distribution half life 12 minutes, elimination half 100 minutes |excretion= |pregnancy_AU=<!-- A / B1 / B2 / B3 / C / D / X --> |pregnancy_US=<!-- A / B / C / D / X --> |pregnancy_category= |legal_AU=<!-- Unscheduled / S2 / S4 / S8 --> |legal_UK=<!-- GSL / P / POM / CD --> |legal_US=<!-- OTC / Rx-only --> |legal_status= |routes_of_administration=}} |
|||
''' |
'''Gadopentetic acid''' (also known as '''Gadopentetate dimeglumine''' or '''Gd-DTPA''') is the first paramagnetic [[magnetic resonance imaging]] (MRI) [[contrast agent]]. First described in 1981, and introduced in 1988, it is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing [[intracranial]] [[lesion]]s with abnormal [[blood vessel|vascularity]] or abnormalities in the [[blood-brain barrier]]. It is usually injected intravenously. Gd-DTPA is a [[gadolinium]] complex of diethylenetriamine pentaacetic acid and is classed as an acyclic, ionic gadolinium contrast medium. Its [[paramagnetic]] property reduces the [[Spin-lattice relaxation time|T1]] [[Relaxation (NMR)|relaxation time]] (and to some extent the T2 and T2* relaxation times) in [[NMR]], which is the source of its clinical utility. |
||
Marketed as Magnevist by |
Marketed as Magnevist by Bayer Schering Pharma, it was the first intravenous contrast agent to become available for clinical use, and is in widespread use around the world. |
||
Gadolinium based agents may cause a toxic reaction known as [[Nephrogenic Systemic Fibrosis]] ([[NSF]]) in patients with severe kidney problems.<ref name="murphy">{{cite journal | author=Murphy KJ, Brunberg JA, Cohan RH | title=Adverse reactions to gadolinium contrast media: a review of 36 cases | journal=American Journal of Roentgenology | year=1996 | volume=167 | pages=847-849}}</ref><ref name="thomsen">{{cite journal | author=H.S. Thomsen, S.K. Morcos and P. Dawson | title=Is there a causal relation between the administration of gadolinium-based contrast media and the development of nephrogenic systemic fibrosis (NSF)? | journal=Clinical Radiology | volume=61 | issue=11 | month=Nov | year=2006 | pages=905-906}}</ref> |
Gadolinium based agents may cause a toxic reaction known as [[Nephrogenic Systemic Fibrosis]] ([[NSF]]) in patients with severe kidney problems.<ref name="murphy">{{cite journal | author=Murphy KJ, Brunberg JA, Cohan RH | title=Adverse reactions to gadolinium contrast media: a review of 36 cases | journal=American Journal of Roentgenology | year=1996 | volume=167 | pages=847-849}}</ref><ref name="thomsen">{{cite journal | author=H.S. Thomsen, S.K. Morcos and P. Dawson | title=Is there a causal relation between the administration of gadolinium-based contrast media and the development of nephrogenic systemic fibrosis (NSF)? | journal=Clinical Radiology | volume=61 | issue=11 | month=Nov | year=2006 | pages=905-906}}</ref> |
||
Line 10: | Line 11: | ||
==External links== |
==External links== |
||
*[http://www. |
*[http://www.imaging.bayerhealthcare.com/html/magnevist/index.html?WT.mc_id=berleximaging.com Bayer Healthcare Pharmaceuticals page on Magnevist] |
||
*{{cite web |
*{{cite web |
||
| url = http://www.mr-tip.com/serv1.php?type=db1&dbs=Gadopentetate%20Dimeglumine |
| url = http://www.mr-tip.com/serv1.php?type=db1&dbs=Gadopentetate%20Dimeglumine |
Revision as of 13:57, 30 July 2008
Pharmacokinetic data | |
---|---|
Elimination half-life | Distribution half life 12 minutes, elimination half 100 minutes |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H54GdN5O20 |
Gadopentetic acid (also known as Gadopentetate dimeglumine or Gd-DTPA) is the first paramagnetic magnetic resonance imaging (MRI) contrast agent. First described in 1981, and introduced in 1988, it is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood-brain barrier. It is usually injected intravenously. Gd-DTPA is a gadolinium complex of diethylenetriamine pentaacetic acid and is classed as an acyclic, ionic gadolinium contrast medium. Its paramagnetic property reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility.
Marketed as Magnevist by Bayer Schering Pharma, it was the first intravenous contrast agent to become available for clinical use, and is in widespread use around the world.
Gadolinium based agents may cause a toxic reaction known as Nephrogenic Systemic Fibrosis (NSF) in patients with severe kidney problems.[1][2]
References
- ^ Murphy KJ, Brunberg JA, Cohan RH (1996). "Adverse reactions to gadolinium contrast media: a review of 36 cases". American Journal of Roentgenology. 167: 847–849.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ H.S. Thomsen, S.K. Morcos and P. Dawson (2006). "Is there a causal relation between the administration of gadolinium-based contrast media and the development of nephrogenic systemic fibrosis (NSF)?". Clinical Radiology. 61 (11): 905–906.
{{cite journal}}
: Unknown parameter|month=
ignored (help)
External links
- Bayer Healthcare Pharmaceuticals page on Magnevist
- "Gadopentetate Dimeglumine". Magnetic Resonance - Technology Information Portal. Retrieved 2006-03-27.